Homology Medicines Presents on Design of pheEDIT Trial Evaluating One-Time Nuclease-Free Gene Editing Candidate HMI-103 for PKU at American Society of Human Genetics Meeting

Stock Information for Homology Medicines Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Homology Medicines Inc.

Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Homology Medicines, Inc. (FIXX) and Encourages Long-Term FIXX Investors to Contact the Firm
Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights
Homology Medicines to Participate at Upcoming Conferences
Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Homology Medicines, Inc. (FIXX) and Encourages Long-Term FIXX Investors to Contact the Firm
Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer
Homology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.